Platform & Pipeline

Developing next-generation CAR T-Cell therapy for a paradigm shift in the treatment of autoimmune diseases.

CAR T cells have the potential for therapeutic breakthrough in

B-cell driven autoimmune diseases.

Kyverna is the exclusive worldwide licensee of a next-generation CAR T construct targeting CD19 for use in autologous (KYV-101) and allogeneic (KYV-201) cell therapies for B-cell driven autoimmune diseases.

A new platform for

CAR T-cell therapy

Both our autologous (KYV-101) and allogeneic (KYV-201) CAR compounds are fully human, autologous anti-CD19 CAR T-cell therapies designed to reduce cytokine release, deplete B cells, and improve clinical tolerability.

Our CAR holds the promise to change the treatment paradigm by potentially delivering deep B-cell depletion and immune reset in patients with B-cell driven autoimmune diseases.

The CAR in KYV-101 and KYV-201 has been designed for improved tolerability with comparable efficacy vs. the leading CAR in oncology.


Currently developing a comprehensive pipeline of B-Cell targeting therapies


Systemic Sclerosis

Myasthenia Gravis

Multiple Sclerosis


How to access the Kyverna treatment platform

Participation in clinical trials is the best way to access our investigational product. Kyverna may consider requests for expanded access when alternative therapy options have been exhausted.